Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Opzelura Is First Topical JAK Inhibitor Approved In US
Executive Summary
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.
You may also be interested in...
Dermavant’s Vtama Appears Well Positioned To Compete With Other Topicals In AD
Approved for psoriasis, Vtama met the primary and secondary endpoints in first of two Phase III atopic dermatitis studies. The Roivant affiliate will position the drug as a two-in-one solution for both.
Incyte Signals Increasing Focus In Dermatology With Villaris Buyout
With Opzelura approved for vitiligo in July, Incyte acquires Villaris and its preclinical IL-15-targeted antibody to potentially add to its vitiligo portfolio.
Incyte Bolsters Dermatology Ambitions With Vitiligo Approval For Topical Ruxolitinib
Opzelura, already approved for atopic dermatitis, gives Incyte a second indication for its topical JAK inhibitor. It is the first treatment approved for vitiligo.